The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/23133

Please be advised that this information was generated on 2019-02-28 and may be subject to change.
The effects of 5-fluorouracil and interferon-α on early healing of experimental intestinal anastomoses

JWD de Waard*, T Wobbes, BM de Man, CJ van der Linden and T Hendriks

Department of Surgery, University Hospital Nijmegen, Nijmegen, The Netherlands.

Summary  The continuing search for effective adjuvant therapy after resection of intestinal malignancies has prompted a growing interest in both immediate post-operative regional chemotheraphy and the combination of 5-fluorouracil (5-FU) and interferon-α as drugs of choice. We have compared the effects of both compounds, alone and together, on early healing of intestinal anastomoses. Four groups (n = 26 each) of rats underwent resection and anastomosis of both ileum and colon: a control group and three groups receiving intraperitoneal 5-FU, interferon-α or both on the day of surgery and the next 2 days. Animals were killed 3 or 7 days after operation in order to measure anastomotic strength and hydroxyproline content. The remaining six animals in each group were used to study anastomotic collagen synthetic capacity at day 3. Three days after operation, ileal anastomotic bursting pressure was lowered by 37% in the 5-FU/interferon-α group (P = 0.0104). At day 7, anastomotic breaking strength was reduced significantly in ileum (P = 0.0221) and colon (P = 0.0054) of the 5-FU/interferon-α group and in colon of the interferon-α group (P = 0.0221). Collagen synthetic capacity was strongly suppressed by 5-FU but not by interferon-α. However, no differences in anastomotic hydroxyproline content were observed between groups at both days 3 and 7. Thus, post-operative use of interferon-α, in particular in combination with 5-FU, may be detrimental to anastomotic repair in the intestine.

Keywords: anastomosis; collagen; fluorouracil; interferon-α; intestine

Despite the high resectability rate and general improvement in surgical therapy, nearly half of all patients with colorectal cancer will eventually die from recurrent disease. Candidates for post-operative adjuvant therapy are patients at risk for disease relapse, as judged by clinical evaluation, surgical examination and pathological examination of resection specimens. In general, safe and effective adjuvant therapy would be highly desirable in patients with Dukes' stage B2 and C colon carcinoma, which constitute 60 - 70% of the population presenting with colorectal cancer.

Over the last three decades numerous studies have shown little or no survival benefit, although small but significant clinical improvement, from post-operative regional chemotheraphy using 5-fluorouracil (5-FU) as the primary agent (Kemeny et al., 1993; Moertel, 1994). Presently, preclinical and clinical protocols aim to increase the activity of 5-FU-based adjuvant therapy. The optimal manner in which 5-FU should be administered still remains to be determined. There appear to be excellent reasons to start treatment immediately after operation (Harris and Mastrangelo, 1991) and to administer drugs intraperitoneally (Cunliffe and Sugarbaker, 1989). Indeed, a survey of ongoing European trials shows increasing interest in treatment modalities that include immediate post-operative regional chemotheraphy (Pählman, 1995).

Much effort has also been directed at enhancing the activity of 5-FU by drugs such as leucovorin and levamisole. Recently, the potential of the interferons has been recognised in this respect. Interferons are a family of multifunctional proteins and components of the host defence against viral and parasitic infections and malignancy (Sen and Lengyel, 1992). In vitro studies have demonstrated that each type of interferon may interact with fluoropyrimidines in a synergistic manner to produce cytotoxicity in a variety of human cancer cell lines (see Grem et al., 1995). In phase II trials in patients with advanced colorectal carcinoma the combination of interferon-α, plus or minus leucovorin, with 5-FU appears to possess higher activity than 5-FU alone (Grem et al., 1991; Pazdur, 1991; Wadler et al., 1991). This increased activity is the result of biochemical modulation of 5-FU metabolism, with both enhancement of the inhibition of thymidylate synthase and alteration of the pharmacokinetics of 5-FU being described.

Accepting the hypothesis that immediate post-operative administration of interferon-α, together with 5-FU, might benefit patients after resection of colorectal carcinoma, it becomes essential to investigate the potential effects of these drugs on early anastomotic healing in the intestine. Loss of wound strength increases the risk for anastomotic dehiscence, which is a most serious surgical complication with concomitant high mortality and morbidity. Previous experiments in our laboratory have shown that perioperative intraperitoneal combination chemotherapy containing 5-FU severely reduces early anastomotic strength (de Rey van Zuidewijn et al., 1991). In addition, daily intraperitoneal 5-FU alone from the day of operation onwards strongly inhibits anastomotic repair in the rat intestine (Grat et al., 1992; de Waard et al., 1995b). If administration of 5-FU remains limited to the day of operation and the first two post-operative days anastomotic strength is not significantly affected (de Waard et al., 1993). In a recent experiment we have examined the effects of 5-FU plus levamisole or leucovorin on anastomotic healing (de Waard et al., 1995b). Here, we describe our experiments into the effects of a 3 day post-operative course of interferon-α and interferon-α plus 5-FU on early healing of intestinal anastomoses in the rat.

Materials and methods

Animals

Altogether, 104 male outbred Wistar/Cpb:WU rats, weighing between 200 and 300 g, were used. They were housed with two animals per cage and had free access to water and standard laboratory chow (diet AM II, Hope farms, Woerden, The Netherlands).

For the measurement of anastomotic strength and hydroxyproline content, 80 animals were randomly divided
into four groups of 20 animals each: a control group, a 5-FU group, an interferon group and a group receiving 5-FU plus interferon. Within each group, ten rats were killed at 3 and 7 days after operation. Collagen synthesis was measured in similar groups of animals (n = 6 each in each group). These rats were killed 3 days after operation. The study was approved by the Animal Ethics Review Committee of the Faculty of Medicine, University of Nijmegen.

Drug administration
5-FU (Abic, Netanya, Israel) was given intraperitoneally in a dose of 20 mg kg⁻¹ body weight (concentration: 1 mg ml⁻¹ saline). This is the same dose we used before (de Waard et al., 1993, 1995a,b) and represents the highest dose which, in combination with surgery, did not result in a significant mortality. Recombinant rat interferon-α (van der Meide et al., 1986; specific activity 6 x 10⁸ U mg⁻¹ protein) was administered intraperitoneally in a dose of 2 x 10⁶ U kg⁻¹ body weight (concentration: 2 x 10⁴ U ml⁻¹ saline). The drugs were given once a day, on the day of operation and the next 2 days. The animals in the control groups received intraperitoneal saline daily.

Operative procedure
After an intraperitoneal injection of sodium pentobarbital, a midline incision was made and 1 cm of both small and large bowel was resected, at 15 cm proximal to the ileocecal junction, and 3 cm proximal to the rectal peritoneal reflection respectively. Continuity was restored microsurgically by the construction of an inverted one-layer seromuscular end-to-end anastomosis with eight interrupted sutures of 8 x 0 monofilament material (Ethicon, Sommerville, USA). The abdomen was closed in two layers with a continuous 3 x 0 silk suture for the fascia and staples for the skin.

Analytical procedures
The rats were killed by an intraperitoneal overdose of sodium pentobarbital. After opening the abdominal wound and identifying the anastomoses, the adhesions were cut as far as possible without injuring the intestine. An intestinal segment with the anastomosis in the middle was removed, with the sutures left in place. This segment was attached to an infusion pump filled with methylene blue-stained saline. The pressure was raised with an infusion rate of 4 ml min⁻¹ and recorded graphically. Both the bursting pressure, i.e. the maximum pressure recorded immediately before sudden loss of pressure, and the site of rupture were noted. Thereafter, the segment was placed in a tensiometer, and the breaking strength was recorded. Thus, both the bursting pressure and breaking strength were measured in the same anastomotic segment. The validity of this procedure has been confirmed in a pilot experiment. Anastomotic breaking strength was compared in two groups of rats, either measured directly or after the procedure used for measuring the bursting pressure, and found to be similar in both groups (de Waard et al., 1995b). The anastomotic segment was then cleaned from the surrounding tissue and a 5 mm segment with the suture line in the middle was collected. The samples were frozen immediately and stored in liquid nitrogen until processing. After weighing, the samples were pulverised and lyophilised.

Relative collagen synthesis (RCS) was calculated in four groups of 20 animals each: a control group, a 5-FU group, an interferon group and a group receiving 5-FU plus interferon. Significant differences (P < 0.033, see Materials and methods) between groups are denoted by # (interferon-α control group), * (5-FU w control group) and $ (5-FU w FU/interferon-α group).

Results
No animals died prematurely during the experimental protocol. Up to 24 h after operation, all rats lost approximately 8% of their body weight. Thereafter, animals regained weight, although clear differences were observed between groups (Figure 1). Weight gain in the 5-FU group was significantly slower than in the control group. Administration of

was counted. Subsequently, in order to determine proline incorporation into collagen, excess purified collagenase was added. The radioactivity in the supernatant represents CDP, as a measure of the amount of collagen synthesised. Subtraction of the radioactivity in the CDP fraction from that in total protein yields the incorporation into non-collagenous protein (NCP). The relative collagen synthesis (RCS) was calculated with the formula (Peterkofsky et al., 1981) that takes into account the enrichment of proline in collagen compared with other proteins:

Relative collagen synthesis (%) = \( \frac{\text{CDP}}{\text{NCP} \times 5.4 + \text{CDP}} \times 100 \)

Incorporation is expressed on the basis of sample wet weight, DNA (Burton, 1956) content or protein (Smith et al., 1985) content.

Statistical analysis
To correct for the fact that multiple comparisons were made, pairwise comparisons of groups were performed (with a two-tailed Mann–Whitney test) using a level of significance of \( \alpha' = 2\alpha/k \), where \( k \) is the number of pairwise comparisons. For instance, differences between the three experimental groups and the control group (Figures 2–4) were considered significant (\( \alpha = 0.05 \)) at \( P < \alpha' \), where \( \alpha' = 2 \times 0.05/3 = 0.033 \).

![Figure 1](image-url)  
Figure 1 Course of body weight. Data represent mean values (n = 10) and, for the control group only, the s.d. (O), control group; (●), interferon-α group; (△), 5-FU group; (▲), 5-FU/interferon-α group. Significant differences (P < 0.033, see Materials and methods) between groups are denoted by # (interferon-α control group), * (5-FU w control group) and $ (5-FU w 5-FU/interferon-α group).
interferon-α appeared to increase the rate of weight gain over the first post-operative days: mean body weight was significantly higher in the interferon-α group than in the control group from day 3 onwards, and in the 5-FU/interferon-α group than in the 5-FU group from day 5 onwards.

Anastomotic strength may be assessed both from the bursting pressure, which represents its resistance to intraluminal pressure, and from the breaking strength, which reflects its ability to withstand longitudinal forces.

Figure 2 depicts the outcome of all measurements of anastomotic bursting pressure performed at 3 days after operation. At this time the bursting site was always within the anastomotic area. In altogether six (out of 80) anastomoses the bursting pressure could not be measured because of technical problems. Neither 5-FU nor interferon-α administration led to a significant change in bursting pressure. However, the mean bursting pressure of ileal anastomoses in the 5-FU/interferon-α group (44 ± 7 mmHg) was significantly (P = 0.0104) lower than that in the control group (70 ± 20 mmHg). In addition, it was also significantly reduced with respect to the 5-FU group (P = 0.0037) and the interferon-α group (P = 0.0062). In colon, these differences did not reach statistical significance. At 7 days after operation the bursting site was always outside the suture line and therefore the bursting pressures measured (data not shown) did not reflect actual wound strength.

When measuring the breaking strength (Figure 3) the breaking site was invariably located within the wound area. At 3 days after operation no differences were found between groups, but after 7 days the breaking strength of both ileal and colonic anastomoses was significantly lower in the 5-FU/interferon-α group than in the control group. Also, anastomotic breaking strength in the colon was reduced in the interferon-α group.

The hydroxyproline content in 5 mm segments containing the anastomosis was quantitated as a measure of wound collagen levels (Figure 4). No differences between the control group and the experimental groups were observed. The hydroxyproline content increased similarly from 3 to 7 days after operation independent of medication. Likewise, no differences were found for hydroxyproline concentrations. Mean hydroxyproline concentrations were 7.0 ± 1.3 and 9.6 ± 1.8 μg mg⁻¹ dry weight in 3- and 7-day-old ileal anastomoses respectively; corresponding values in colonic

Figure 2 Anastomotic bursting pressure after 3 days. Points represent measurements in individual animals with bars indicating mean values. *Significantly (P < 0.033, see Materials and methods) different from control group.

Figure 3 Anastomotic breaking strength. Bars represent mean values (n = 9 or 10) ± s.d. 1, control group; 2, 5-FU group; 3, interferon-α group; 4, 5-FU/interferon-α group. *Significantly (P < 0.033, see Materials and methods) different from control group.

Figure 4 Anastomotic hydroxyproline content. Bars represent mean values (n = 10) ± s.d. 1, control group; 2, 5-FU group; 3, interferon-α group; 4, 5-FU/interferon-α group.
The wound healing process is characterised by massive cell migration and proliferation. Cytostatic drugs are by nature drugs of choice (see Grem et al., 1995). The present results indicate that caution should be exerted in the use of interferon-α as an adjunct to 5-FU therapy in the early post-operative period since such treatment might constitute a threat to undisturbed anastomotic healing. The combination of interferon-α and 5-FU, administered intraperitoneally on the day of operation and the first two post-operative days, reduces the development of anastomotic strength during the first week after its construction. Administration of 5-FU alone has no significant deleterious effect on wound strength, but interferon-α in itself significantly lowers strength below control values in 7-day-old colonic anastomoses.

The wound healing process is characterised by massive cell migration and proliferation. Cytostatic drugs are by nature anti-proliferative and may therefore be expected to interfere with wound healing. Indeed, 5-FU administered daily from the day of operation onwards until sacrifice after 7 days severely impairs anastomotic healing in the rat intestine (Graf et al., 1992; de Waard et al., 1995b). In earlier experiments, we tried to mitigate this negative effect by concomitant administration of either interleukin 2 or granulocyte-macrophage colony-stimulating factor, but 5-FU impaired repair was not essentially altered by either cytokine. On the other hand, retinol significantly promoted 5-FU suppressed anastomotic healing (de Waard et al., 1995a). Also, we reported before that the negative effect is limited if 5-FU is given only three times (de Waard et al., 1993, 1995a). Since we expected any additional effect of interferon-α to be observed more easily under the latter conditions, we limited drug administration to the first 3 days.

### Discussion

The continuing search for effective adjuvant therapy after resection of colorectal carcinoma has resulted in a growing interest in the efficacy of both immediate post-operative regional chemotherapy (see Pålman, 1995) and the combination of 5-FU with interferon-α as the cytostatic drugs of choice (see Grem et al., 1995). The present results indicate that caution should be exerted in the use of interferon-α as an adjunct to 5-FU therapy in the early post-operative period since such treatment might constitute a threat to undisturbed anastomotic healing. The combination of interferon-α and 5-FU, administered intraperitoneally on the day of operation and the first two post-operative days, reduces the development of anastomotic strength during the first week after its construction. Administration of 5-FU alone has no significant deleterious effect on wound strength, but interferon-α in itself significantly lowers strength below control values in 7-day-old colonic anastomoses.

The wound healing process is characterised by massive cell migration and proliferation. Cytostatic drugs are by nature anti-proliferative and may therefore be expected to interfere

### Table I

<table>
<thead>
<tr>
<th>Segment</th>
<th>Control segment</th>
<th>Anastomosis</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ileum</td>
<td>D.p.m. µg⁻¹ DNA</td>
<td>41 ± 6</td>
<td>194 ± 30</td>
</tr>
<tr>
<td></td>
<td>D.p.m. mg⁻¹ wet weight</td>
<td>85 ± 24</td>
<td>595 ± 72</td>
</tr>
<tr>
<td></td>
<td>D.p.m. mg⁻¹ protein</td>
<td>2578 ± 654</td>
<td>14786 ± 1953</td>
</tr>
<tr>
<td></td>
<td>RCS (%)</td>
<td>0.47 ± 0.08</td>
<td>1.02 ± 0.16</td>
</tr>
<tr>
<td>Colon</td>
<td>D.p.m. µg⁻¹ DNA</td>
<td>86 ± 18</td>
<td>221 ± 62</td>
</tr>
<tr>
<td></td>
<td>D.p.m. mg⁻¹ wet weight</td>
<td>305 ± 45</td>
<td>773 ± 150</td>
</tr>
<tr>
<td></td>
<td>D.p.m. mg⁻¹ protein</td>
<td>7317 ± 1019</td>
<td>17454 ± 3214</td>
</tr>
<tr>
<td></td>
<td>RCS (%)</td>
<td>1.12 ± 0.12</td>
<td>1.72 ± 0.32</td>
</tr>
</tbody>
</table>

Explants from control segments, collected at operation, and anastomotic tissue, collected 3 days after operation, were incubated for 3 h with 4.5 µCi of ¹⁴Cproline. Collagen synthesis is expressed as radioactivity in collagenase-digestible protein, and as percentage relative collagen synthesis (RCS). Data represent average values (+ s.d.) from six animals.
So far, little is clear about the effects of interferon-a on wound healing. Interferon-γ, delivered intraperitoneally through an osmotic pump (Granstein et al., 1989) or injected subcutaneously (Miles et al., 1994), has been found to delay skin repair in mice. In the latter study, wound disruption strength was reduced significantly at a dose of $7 \times 10^4$ U kg$^{-1}$ body weight and higher. Two experiments, with opposite results, have been reported on the effects of interferon-α/β on cutaneous healing in rodents. Intramuscular injection of interferon-α/β or intraperitoneal administration of polynucleic-polycondylic acid, a potent inducer of interferon, seemingly enhances repair (Bhartiya et al., 1992), while local subcutaneous injection of interferon-α/β into the wound actually inhibits repair (Stout et al., 1993). In these studies, evaluation of repair was solely on the basis of macroscopic or histological parameters; functional parameters, like wound strength, were not reported.

The present study is the first effort to investigate the effect of purified interferon-α on wound strength. Rat recombinant interferon-α was given in a daily dose of $2 \times 10^5$ U kg$^{-1}$ body weight. This dose is more than sufficient to protect rats against a lethal pseudorabies virus (PHV van der Meide, personal communication), but is substantially lower than the doses of interferon employed in the studies mentioned above. Still, daily doses of this relatively low dose of interferon-α, administered on the first three post-operative days, significantly reduce anastomotic breaking strength in the colon 7 days after operation. The results of treatment with the combination of 5-FU and interferon-α are probably of more immediate interest in terms of potential treatment of patients with colorectal cancer. It seems clear that addition of 5-FU and interferon-α are probably of more clinical application of 5-FU plus interferon-α immediately after anastomotic construction, although possibly beneficial with the uninjured intestine; it remains to be determined how exactly interferon-α interferes with the healing sequence. The strength of both the side-effects with respect to wound repair.

It remains to be determined how exactly interferon-α interferes with the healing sequence. The strength of both the uninjured and the sutured bowel wall depends to a large extent on collagen and anastomotic construction leads very quickly to an increased collagen synthetic capacity within the wound area (Martens and Hendriks, 1991). Interferons are known to be able to inhibit collagen synthesis (Granstein et al., 1990). This suppressive effect is well established by in vitro experiments with fibroblasts (Jimenez et al., 1984; Duncan and Berman, 1985), which are the primary producers of extracellular matrix in the healing wound. Indeed, histological examination of interferon-α-treated wounds indicates reduced accumulation of collagen (Granstein et al., 1989; Miles et al., 1994). However, our data show that treatment with interferon-α alone does not lead to lowering of either ex vivo collagen synthetic capacity in anastomotic explants or hydroxyproline accumulation in anastomotic segments. Such an effect is indeed observed after 5-FU treatment, but again addition of interferon-α does not lead to further reduction. This lack of effect of interferon-α may be explained by the relatively low doses we used. Alternatively, it could be that interferon-α has less effect on matrix production than the other interferons. Experiments with isolated cells show this to be true for fibroblast collagen synthesis, both on the protein (Jimenez et al., 1984; Duncan and Berman, 1985) and the mRNA level (Duncan et al., 1995).

Anastomotic strength will also be affected by degradation of the existing matrix anchoring the sutures. The methodology used to measure the hydroxyproline content in anastomotic segments, which necessarily contain unjured tissue next to the actual wound area, does not allow the detection of very localised loss of collagen. It may be that interferon-α increases collagenase expression (Duncan and Berman, 1989; Hujanen et al., 1994), although macrophage metalloproteinase production appears to be inhibited by interferon-γ (Wahl and Corcoran, 1993).

Finally, one could speculate that interferon-α interferes with healing by the inhibition of proliferation, either directly or by biochemical modulation of 5-FU metabolism. Interferons are growth inhibitors for a variety of normal and transformed cell lines (see Mallat et al., 1995). The impairment of cutaneous healing by interferon-α/β is thought to be caused primarily by inhibition of proliferation of all cell types involved in wound repair (Stout et al., 1993). More specifically, interferon-α is known to inhibit endothelial cell proliferation and thereby angiogenesis (Polkman, 1995), processes inherent to successful repair.

Whatever the mechanism(s) responsible, our data clearly indicate that administration of interferon-α in the periperaoperative period may be detrimental to anastomotic repair and that its use in immediate post-operative adjunct therapy, as a means to enhance 5-FU activity, should be approached with caution.

Acknowledgement The authors are grateful to Dr PH van der Meide (Institute of Applied Radiobiology and Immunology TNO, Rijswijk, The Netherlands) for his gift of rat recombinant interferon-α.

References


